{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:05:41Z","timestamp":1772197541208,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Dapagliflozin has been used to treat patients with type 1 diabetes mellitus; however, the actual drug efficacy of dapagliflozin on glycated hemoglobin (HbA1c) and whether there is a rebound from dapagliflozin efficacy on HbA1c remain unknown. The present study aimed to explore the actual therapeutic effect and rebound situation of dapagliflozin on HbA1c in type 1 diabetes mellitus patients. A total of 1,594 type 1 diabetes mellitus patients were enrolled for analysis using a non-linear mixed effect model from randomized controlled trials from published literature works including two 5\u00a0mg\/day dapagliflozin dosage groups and three 10\u00a0mg\/day dapagliflozin dosage groups. The change rate of HbA1c from a baseline value was chosen as a dapagliflozin pharmacodynamic evaluation index. After deducting control group effects, the therapeutic effect of 5 and 10\u00a0mg\/day dapagliflozin on HbA1c in type 1 diabetes mellitus patients had no significant difference. In addition, the actual maximal efficacy (AE<jats:sub>max<\/jats:sub>) of dapagliflozin on HbA1c was -6.24% at week 9. When it reached the AE<jats:sub>max<\/jats:sub>, the dapagliflozin pharmacodynamic rebound on HbA1c occurred, and when the treatment was continued for 0.5 and 1\u00a0year, the actual efficacies were -4.70% (75% AE<jats:sub>max<\/jats:sub>) and -3.27% (52% AE<jats:sub>max<\/jats:sub>), respectively. This was the first time to clarify the actual therapeutic effect and rebound situation of dapagliflozin on HbA1c in type 1 diabetes mellitus patients, providing a reference value for clinical practices.<\/jats:p>","DOI":"10.3389\/fphar.2022.972878","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:28:21Z","timestamp":1672838901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Dong-Dong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Mei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2337\/cd18-0105","article-title":"Standards of medical care in diabetes-2019 abridged for primary care providers","volume":"37","year":"2019","journal-title":"Clin. Diabetes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/dom.14362","article-title":"Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in japanese patients with type 1 diabetes: subgroup analysis of the DEPICT-2 study","volume":"23","author":"Araki","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/dom.13922","article-title":"Efficacy and safety of dapagliflozin in japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial","volume":"22","author":"Araki","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/dom.14258","article-title":"Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: the DAPADream study","volume":"23","author":"Biester","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.21037\/atm-21-4124","article-title":"Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation","volume":"9","author":"Chen","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"758524","DOI":"10.3389\/fphar.2022.758524","article-title":"Effects of posaconazole on tacrolimus population pharmacokinetics and initial dose in children with Crohn's disease undergoing hematopoietic stem cell transplantation","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.2337\/dc22-1157","article-title":"Dapagliflozin improves the urinary proteomic kidney-risk classifier CKD273 in type 2 diabetes with albuminuria - a randomized clinical trial","volume":"45","author":"Curovic","year":"2022","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-Week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/MED.0000000000000669","article-title":"Carbohydrate-restricted diets and type 1 diabetes mellitus: research considerations","volume":"28","author":"Dikeman","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/obr.12606","article-title":"Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines","volume":"18","author":"Dong","year":"2017","journal-title":"Obes. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3389\/fendo.2019.00592","article-title":"Environmental factors associated with type 1 diabetes","volume":"10","author":"Esposito","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/jpm12020223","article-title":"Evidence for cardiorenal protection with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetic kidney disease","volume":"12","author":"Georgianos","year":"2022","journal-title":"J. Pers. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/dom.14377","article-title":"Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors","volume":"23","author":"Ghanim","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"109791","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0263285","DOI":"10.1371\/journal.pone.0263285","article-title":"SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes","volume":"17","author":"Hodrea","year":"2022","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1358\/dot.2022.58.2.3369188","article-title":"An update on dapagliflozin for chronic kidney disease","volume":"58","author":"Kelly","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as additional treatment to Liraglutide and insulin in patients with type 1 diabetes","volume":"101","author":"Kuhadiya","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"106374","DOI":"10.1016\/j.phrs.2022.106374","article-title":"Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study","volume":"183","author":"Lazzaroni","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bbrc.2016.09.106","article-title":"Perivascular adipose tissue alleviates inflammatory factors and stenosis in diabetic blood vessels","volume":"480","author":"Li","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"923376","DOI":"10.3389\/fendo.2022.923376","article-title":"A Network meta-analysis of the dose-response effects of dapagliflozin on efficacy and safety in adults with type 1 diabetes","volume":"13","author":"Li","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12165","DOI":"10.3390\/ijms222212165","article-title":"Micro-RNA implications in type-1 diabetes mellitus: A review of literature","volume":"22","author":"Margaritis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/jcph.2062","article-title":"Dapagliflozin pharmacokinetics is similar in adults with type 1 and type 2 diabetes mellitus","volume":"62","author":"Melin","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"106954","DOI":"10.1016\/j.vph.2022.106954","article-title":"Diabetic neuropathy: molecular approach a treatment opportunity","volume":"143","author":"Mendez-Morales","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2337\/dc15-0078","article-title":"Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry","volume":"38","author":"Miller","year":"2015","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s40265-019-01213-x","article-title":"Dapagliflozin: a review in type 1 diabetes","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/dom.13664","article-title":"Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus","volume":"21","author":"Parkinson","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"B30","doi-asserted-by":"publisher","first-page":"783065","DOI":"10.3389\/fmolb.2021.783065","article-title":"Metabolic and metabolomic insights regarding the omega-3 PUFAs intake in type 1 diabetes mellitus","volume":"8","author":"Purdel","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00125-022-05650-4","article-title":"Endothelial glycocalyx is damaged in diabetic cardiomyopathy: angiopoietin 1 restores glycocalyx and improves diastolic function in mice","volume":"65","author":"Qiu","year":"2022","journal-title":"Diabetologia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dc22-0829","article-title":"High HbA1c levels are associated with development of trigger finger in type 1 and type 2 diabetes: an observational register-based study from sweden","volume":"45","author":"Rydberg","year":"2022","journal-title":"Diabetes Care"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.it.2013.08.005","article-title":"Immune mechanisms in type 1 diabetes","volume":"34","author":"Wallberg","year":"2013","journal-title":"Trends Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jcpt.13572","article-title":"Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients","volume":"47","author":"Wang","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"611480","DOI":"10.3389\/fphar.2021.611480","article-title":"Analysis of time course and dose effect from Metformin on body Mass index in children and adolescents","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e14866","DOI":"10.1111\/dme.14866","article-title":"Type 2 diabetes medication and HbA1c levels in North Karelia Finland, 2013-2019","volume":"39","author":"Wikstrom","year":"2022","journal-title":"Diabet. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9681034","DOI":"10.1155\/2022\/9681034","article-title":"A Classification tree model with optical coherence tomography angiography variables to Screen Early-Stage diabetic Retinopathy in diabetic patients","volume":"2022","author":"Yao","year":"2022","journal-title":"J. Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.972878\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:28:26Z","timestamp":1672838906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.972878\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":38,"alternative-id":["10.3389\/fphar.2022.972878"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.972878","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"972878"}}